Most Popular - Shares of ResMed Inc. (RMD) have finally found their top, peaking at $48.37 in late January before dropping to the $43 level. But the downslide … Continue Reading
Read nowLong Ideas - Achillion Pharmaceuticals (ACHN) reported positive clinical trial results for ACH-3102, the company’s NS5A inhibitor for hepatitis C (HCV). Achillion remains a leading independent mid-stage biotech … Continue Reading
Read nowLong Ideas - Shares of Pharmacyclics (PCYC), based in Sunnyvale, California, have certainly had a sunny year, rising over 266% in the past 12 months on the back … Continue Reading
Read nowLong Ideas - Earlier this week I had the pleasure of speaking with Alan Shortall, President and CEO of Unilife (NASDAQ:UNIS), about the company’s short and long-term prospects. … Continue Reading
Read nowLong Ideas - Shares of Navidea Biopharmaceuticals (NASDAQ:NAVB) are ready to climb as the PDUFA (FDA action) date for the company’s lead product, Lymphoseek, is approaching. This is … Continue Reading
Read nowLong Ideas - In medicine, there are certain watershed moments that become an enduring part of medical history, such as the discovery of penicillin, or the eradication of … Continue Reading
Read nowLong Ideas - AbbVie (NYSE:ABBV), the R&D-focused spinoff of Abbot Laboratories (NYSE:ABT), began its first day of trading on the NYSE on Wednesday, and we expect shares of … Continue Reading
Read now